Singular Genomics Systems (NASDAQ:OMIC) Shares Gap Down to $11.10

Singular Genomics Systems, Inc. (NASDAQ:OMIC) gapped down prior to trading on Thursday . The stock had previously closed at $11.10, but opened at $9.99. Singular Genomics Systems shares last traded at $9.23, with a volume of 1,764 shares.

Wall Street Analyst Weigh In

Several research firms have commented on OMIC. The Goldman Sachs Group reduced their price objective on Singular Genomics Systems from $25.50 to $22.50 and set a “neutral” rating on the stock in a report on Wednesday, May 15th. UBS Group raised their price objective on Singular Genomics Systems from $12.00 to $15.00 and gave the stock a “neutral” rating in a report on Wednesday, March 20th.

Singular Genomics Systems Trading Down 16.8 %

The firm has a fifty day simple moving average of $11.30 and a 200 day simple moving average of $13.43. The company has a current ratio of 10.35, a quick ratio of 9.54 and a debt-to-equity ratio of 0.05.

Singular Genomics Systems (NASDAQ:OMIC) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($10.20) earnings per share (EPS) for the quarter. Singular Genomics Systems had a negative net margin of 3,863.90% and a negative return on equity of 51.10%. The company had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $0.50 million.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Singular Genomics Systems stock. Weil Company Inc. grew its stake in Singular Genomics Systems, Inc. (NASDAQ:OMIC) by 16.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 138,202 shares of the company’s stock after acquiring an additional 20,000 shares during the quarter. Weil Company Inc. owned about 0.19% of Singular Genomics Systems worth $64,000 at the end of the most recent quarter. 65.80% of the stock is currently owned by institutional investors and hedge funds.

About Singular Genomics Systems

Singular Genomics Systems, Inc, a life science technology company, develops next generation sequencing and multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables for applications comprising single cell gene expression and proteomics, in situ RNA sequencing, and spatial RNA and proteomics applications for tissue.